Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy

Abstract

URL: http://www.clinicaltrials.gov. Unique identifier: NCT02467387.

Effect of Stem Cell Therapy on Patients’ Quality of Life in Heart Failure with Reduced Ejection Fraction

“…[13–18]. The Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial aimed to validate cardiopoiesis-based biotherapy in a larger heart failure cohort.…”

Cardiac Cell Therapy Evolving From Complex to Straightforward

“…In parallel with the Butler et al study earlier this year 3 , exploring intravenous delivery of BM-MSCs, early suggestions of physiological effect shown both clinically and by biomarkers in the Bertolucci study are particularly exciting. Taken together, these two reports provide data to jointly support the notion that an intravenously administered cellular therapy can be effective for patients with severe degrees of heart failure.…”

“…1,2 Earlier this year, a seminal study evaluated the safety and feasibility of intravenous BM-MSC administration in non-ischemic cardiomyopathy 3 , and gathered initial evidence supporting the ability of such an approach to ameliorate inflammation and improve functional status. As described in that study and accompanying editorial 4 , the notion of a heart failure therapy based on an allogeneic cell product delivered by IV infusion is extremely attractive, given the practicality and affordability of such delivery on a standard hospital unit, or even in an outpatient setting.…”

“…In addition, except for the Butler et al trial 3 , and as pointed out by the accompanying editorial 4 , all cell-based approaches to date in patients with advanced to end-stage heart failure have been designed using local myocardial delivery, and thus require resource-intensive, time-consuming, and very costly approaches with catheter-based intramyocardial delivery technology (e.g, NOGA), interventional cardiology skills, available catheterization laboratory facilities, and typically inpatient hospitalization. These features render such approaches difficult to upscale, even if they prove highly effective.…”

Is There a Role for Intravenous Stem Cell Delivery in Nonischemic Cardiomyopathy?

“…In this issue of Circulation Research , Butler, Epstein and colleagues (9) administered allogeneic ischemia-tolerant MSCs (itMSCs) (1.5 × 10 6 cells / kg) by IV in fusion in 22 patients with non-ischemic cardiomyopathy. This is the first cardiovascular cell therapy trial to utilize MSCs cultured under hypoxic condition, thus mimicking the hypoxic microenvironment in the bone marrow.…”